📚 Gene Therapy: Concepts and Clinical Applications | 基因治疗的概念与临床应用
Gene therapy is a revolutionary biomedical approach that aims to treat or prevent disease by modifying the genetic material within a patient’s cells. Instead of relying solely on drugs or surgery, gene therapy seeks to correct the underlying genetic cause of a disorder at the molecular level.
基因治疗是一种革命性的生物医学方法，旨在通过修改患者细胞内的遗传物质来治疗或预防疾病。它不是仅仅依靠药物或手术，而是试图在分子水平上纠正疾病的根本遗传原因。
1. Core Concepts of Gene Therapy | 基因治疗的核心概念
Gene therapy involves the introduction, removal, or alteration of genetic material within a cell to produce a therapeutic effect. The fundamental idea is that if a disease is caused by a faulty gene, we can fix that gene or replace it with a functioning copy.
基因治疗涉及在细胞内引入、移除或改变遗传物质以产生治疗效果。其基本理念是：如果疾病由有缺陷的基因引起，我们就可以修复该基因或用功能正常的拷贝替代它。
There are two major categories of gene therapy based on the target cell type:
根据靶细胞类型，基因治疗可分为两大类：
- Somatic gene therapy: Targets non-reproductive cells (e.g., lung, liver, muscle cells). Changes are not passed to offspring.
- 体细胞基因治疗：针对非生殖细胞（如肺、肝、肌肉细胞）。其改变不会遗传给后代。
- Germline gene therapy: Targets sperm or egg cells. Changes are heritable, raising significant ethical concerns. Currently not permitted in many countries.
- 生殖系基因治疗：针对精子或卵细胞。其改变是可遗传的，引发重大伦理争议。目前在许多国家不被允许。
2. The Genetic Basis of Disease | 疾病的遗传基础
Many diseases arise from mutations in specific genes. A mutation can lead to the production of a non-functional protein, reduced protein levels, or even a toxic gain of function. Classic examples include cystic fibrosis (CF), caused by mutations in the CFTR gene, and sickle-cell anaemia, caused by a point mutation in the β-globin gene.
许多疾病源于特定基因的突变。突变可导致非功能性蛋白质的产生、蛋白质水平降低，甚至产生有毒的功能增强。典型例子包括由 CFTR 基因突变引起的囊性纤维化（CF），以及由 β-珠蛋白基因点突变引起的镰刀型细胞贫血。
For gene therapy to be effective, the disease should ideally be caused by a single gene defect, the affected gene should be accessible, and the therapeutic gene should be delivered efficiently to the correct cells.
要使基因治疗有效，理想情况下疾病应由单一基因缺陷引起，受影响的基因应易于接近，并且治疗基因应被高效地递送到正确的细胞中。
3. Gene Delivery Vectors | 基因递送载体
To deliver therapeutic genes into human cells, scientists use vectors — often modified viruses that can carry genetic material into cells. Viruses are naturally adept at entering cells and delivering their own DNA or RNA, making them ideal starting points.
为了将治疗基因递送入人体细胞，科学家使用载体——通常是经过修饰的病毒，它们能够将遗传物质携带进入细胞。病毒天生擅长进入细胞并递送自身的 DNA 或 RNA，因此是理想的起点。
Viral vector types: adenovirus, adeno-associated virus (AAV), retrovirus, lentivirus
病毒载体类型：腺病毒、腺相关病毒（AAV）、逆转录病毒、慢病毒
| Vector | Advantages | Disadvantages |
| Retrovirus | Integrates into host genome, long-term expression | Only infects dividing cells; risk of insertional mutagenesis |
| Lentivirus | Infects both dividing and non-dividing cells | Insertional mutagenesis risk persists |
| Adenovirus | High transduction efficiency, does not integrate | Short-term expression; strong immune response |
| AAV | Low immunogenicity, long-term expression in non-dividing cells | Small packaging capacity (~4.5 kb) |
4. Ex Vivo vs In Vivo Gene Therapy | 体外与体内基因治疗
Gene therapy can be delivered in two fundamental ways: ex vivo (outside the body) or in vivo (inside the body).
基因治疗可以通过两种基本方式递送：体外（在体外）或体内（在体内）。
Ex vivo approach: Cells are removed from the patient, genetically modified in the laboratory, and then returned to the patient.
体外方法：从患者体内取出细胞，在实验室中进行基因修饰，然后再回输给患者。
In vivo approach: The therapeutic gene is delivered directly into the patient’s body, often via injection of a viral vector.
体内方法：治疗基因直接递送到患者体内，通常通过注射病毒载体实现。
- Ex vivo: Safer, allows selection and verification of corrected cells; useful for blood disorders.
- 体外：更安全，允许选择和验证校正后的细胞；适用于血液疾病。
- In vivo: Simpler delivery, avoids cell culture; useful for tissues like the eye, liver, or muscle.
- 体内：递送更简单，避免了细胞培养；适用于眼、肝或肌肉等组织。
5. Gene Addition vs Gene Editing | 基因添加与基因编辑
Gene addition is the classic form of gene therapy. A functional copy of the gene is added to the genome, but the defective gene remains. This is useful for recessive disorders where one functional copy is sufficient to restore normal phenotype.
基因添加是基因治疗的经典形式。将功能正常的基因拷贝添加到基因组中，但有缺陷的基因仍然存在。这对隐性遗传病非常有用，因为一个功能正常的拷贝就足以恢复正常的表型。
Gene editing, using tools like CRISPR-Cas9, directly repairs or alters the defective DNA sequence. This allows correction of the mutation at its original locus, or even targeted gene disruption for dominant disorders.
基因编辑，使用 CRISPR-Cas9 等工具，直接修复或改变有缺陷的 DNA 序列。这允许在原始位点纠正突变，甚至对显性遗传病进行靶向基因破坏。
CRISPR-Cas9: guide RNA + Cas9 nuclease → DNA double-strand break → HDR or NHEJ
CRISPR-Cas9：向导 RNA + Cas9 核酸酶 → DNA 双链断裂 → 同源定向修复（HDR）或非同源末端连接（NHEJ）
6. Selections: Correcting the Faulty Gene | 修复缺陷基因的选择
When selecting a therapeutic strategy, scientists must consider whether to add, silence, or repair a gene. In dominant disorders, the mutant protein may be harmful, so silencing the mutant gene or precisely editing it is essential.
在选择治疗策略时，科学家必须考虑是添加、沉默还是修复基因。在显性遗传病中，突变蛋白可能是有害的，因此沉默突变基因或精确编辑它就至关重要。
RNA interference (RNAi) is another tool that can silence gene expression at the mRNA level. Small interfering RNAs (siRNAs) can bind to complementary mRNA and trigger its degradation.
RNA 干扰（RNAi）是另一种可以在 mRNA 水平沉默基因表达的工具。小干扰 RNA（siRNA）可以结合互补的 mRNA 并触发其降解。
7. Approved Gene Therapies | 已获批的基因治疗药物
Several gene therapies have now received regulatory approval worldwide, demonstrating the clinical translation of this technology.
目前已有多种基因治疗药物在全球获得监管批准，展示了这项技术的临床转化成果。
| Therapy | Disease | Mechanism |
| Luxturna | Leber congenital amaurosis | AAV-mediated RPE65 gene delivery to retinal cells |
| Zolgensma | Spinal muscular atrophy (SMA) | AAV9 delivery of SMN1 gene |
| CAR-T cell therapies (e.g., Kymriah) | B-cell leukaemia/lymphoma | Lentivirus-mediated CAR gene insertion into T cells |
| Casgevy | Sickle-cell disease / β-thalassaemia | CRISPR-Cas9 editing of BCL11A enhancer |
8. Gene Therapy in Cancer Treatment | 基因治疗在癌症治疗中的应用
Gene therapy has expanded beyond hereditary disorders to oncology. CAR-T cell therapy is a striking example: a patient’s T cells are harvested, genetically engineered to express a chimeric antigen receptor (CAR), and then infused back to attack cancer cells.
基因治疗已从遗传性疾病扩展到肿瘤学领域。CAR-T 细胞疗法是一个突出的例子：从患者体内采集 T 细胞，通过基因工程使其表达嵌合抗原受体（CAR），然后再输回体内以攻击癌细胞。
Tumour suppressor gene therapy and oncolytic virus therapy are additional strategies under investigation. The latter uses viruses that selectively replicate in and destroy tumour cells.
肿瘤抑制基因治疗和溶瘤病毒治疗是另外正在研究中的策略。后者利用选择性在肿瘤细胞内复制并破坏肿瘤细胞的病毒。
9. Risks and Challenges | 风险与挑战
Despite its promise, gene therapy carries significant risks. One major concern is insertional mutagenesis: if the therapeutic gene integrates near an oncogene, it may trigger cancer. This was tragically observed in early X-linked severe combined immunodeficiency (SCID-X1) trials where several patients developed leukaemia.
尽管前景广阔，基因治疗仍存在重大风险。一个主要问题是插入性突变：如果治疗基因整合到癌基因附近，可能引发癌症。在早期 X 连锁重症联合免疫缺陷（SCID-X1）试验中，这种情况曾悲剧性地出现，数名患者发生了白血病。
Immunogenic reactions to viral vectors, off-target editing in CRISPR-based therapies, and limited durability of gene expression are also obstacles. Moreover, the cost of gene therapies remains extremely high, limiting patient access.
病毒载体引发的免疫原性反应、基于 CRISPR 的治疗中的脱靶编辑，以及基因表达持久性有限也是障碍。此外，基因治疗的费用仍然极其高昂，限制了患者的可及性。
10. Ethical Considerations | 伦理考量
Gene therapy raises profound ethical questions. Somatic gene therapy is generally considered acceptable, similar to organ transplantation. However, germline editing is highly controversial because changes are heritable and could affect future generations without their consent.
基因治疗引发了深刻的伦理问题。体细胞基因治疗通常被认为是可以接受的，类似于器官移植。然而，生殖系编辑极具争议性，因为改变是可遗传的，可能会在未经过未来世代同意的情况下对他们产生影响。
Other concerns include the potential for “designer babies” and genetic enhancement, the equitable distribution of expensive therapies, and the long-term ecological and evolutionary consequences of altering the human gene pool.
其他关切包括“定制婴儿”和基因增强的可能性、昂贵疗法的公平分配，以及改变人类基因库的长期生态和进化后果。
11. Future Directions in Gene Therapy | 基因治疗的未来方向
The future of gene therapy is bright. Advances in CRISPR base editing and prime editing allow single-nucleotide changes without double-strand breaks, improving safety and precision.
基因治疗的未来是光明的。CRISPR 碱基编辑和先导编辑技术的进展允许在不产生双链断裂的情况下进行单核苷酸改变，从而提高了安全性和精确性。
Non-viral delivery systems, such as lipid nanoparticle (LNP)-mRNA complexes, are being developed to avoid viral-associated immune responses. The success of mRNA-based COVID-19 vaccines has accelerated this field considerably.
非病毒递送系统，如脂质纳米颗粒（LNP）-mRNA 复合物，正在开发中，以避免与病毒相关的免疫反应。基于 mRNA 的 COVID-19 疫苗的成功极大推动了该领域的发展。
Combining gene therapy with synthetic biology — such as logic-gated circuits that only activate under disease-specific conditions — will enable smarter, safer treatments.
将基因治疗与合成生物学相结合——例如仅在疾病特异性条件下激活的逻辑门控回路——将实现更智能、更安全的治疗。
12. Exam-Style Insights | 考试要点
In A-Level biology examinations, students are often asked to distinguish between somatic and germline gene therapy, describe how viral vectors are used, and evaluate the risks and ethical issues. It is essential to use precise biological terminology and to support your answers with named examples.
在 A-Level 生物考试中，学生经常被要求区分体细胞和生殖系基因治疗，描述病毒载体如何使用，并评估风险和伦理问题。使用精确的生物学术语并用具体例子支持你的答案是至关重要的。
When answering essay questions, always structure your response as: definition → mechanism → vector → example → risks → ethics. Demonstrate understanding of both the molecular basis and clinical context.
回答论述题时，始终按以下结构组织你的答案：定义 → 机制 → 载体 → 例子 → 风险 → 伦理。展示你对分子基础和临床背景两方面的理解。
Published by TutorHao | Biology Revision Series | aleveler.com
更多咨询请联系16621398022（同微信）
屏轩国际教育cambridge primary/secondary checkpoint, cat4, ukiset,ukcat,igcse,alevel,PAT,STEP,MAT, ibdp,ap,ssat,sat,sat2课程辅导，国外大学本科硕士研究生博士课程论文辅导Cancel reply